Literature DB >> 30731128

Cryoglobulinemia: An update in 2019.

Anne Claire Desbois1, Patrice Cacoub1, David Saadoun2.   

Abstract

Cryoglobulinemia is defined as the persistent presence in serum of abnormal immunoglobulins (Igs) that precipitate at low temperatures and dissolve again upon warming. Cryoglobulins may be composed only of a monoclonal Ig (simple type I cryoglobulinemia), of a monoclonal Ig bound to the constant domain of polyclonal Ig heavy chains (mixed type II cryoglobulinemia), or only of polyclonal Igs (mixed type III cryoglobulinemia). The manifestations of type I cryoglobulinemia are often related to intravascular obstruction, whereas those seen in the mixed cryoglobulinemias often originate in true immune complex-mediated vasculitis. The main clinical manifestations affect the skin (purpura, necrotic ulcers), joints, peripheral nervous system, and kidneys (membranoproliferative glomerulonephritis). Patients with type I cryoglobulinemia should be investigated for hematological malignancies (myeloma and B-cell lymphoma). Hepatitis C is the main diagnosis to consider in patients with mixed cryoglobulinemia, followed by connective tissue disease and B-cell non-Hodgkin's lymphoma. The treatment depends mainly on the cause of the cryoglobulinemia. For instance, hepatitis C virus (HCV) eradication is in order in patients with HCV-associated cryoglobulinemia vasculitis, and the underlying hematological malignancy must be treated in patients with type I cryoglobulinemia.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Cryoglobulin; Hematological disease; Hepatitis C; Vasculitis

Mesh:

Substances:

Year:  2019        PMID: 30731128     DOI: 10.1016/j.jbspin.2019.01.016

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  19 in total

1.  Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong.

Authors:  Winston Wing-Shing Fung; Terry Cheuk-Fung Yip; Vincent Wai-Sun Wong; Kai-Ming Chow; Grace Lai-Hung Wong; Cheuk-Chun Szeto
Journal:  Kidney360       Date:  2021-02-22

Review 2.  Skin Changes in Cirrhosis.

Authors:  Adhyatm Bhandari; Rahul Mahajan
Journal:  J Clin Exp Hepatol       Date:  2021-12-28

3.  Cryoglobulinemic purpura and COVID-19 infection.

Authors:  Javier Martín Moyano
Journal:  Med Clin (Engl Ed)       Date:  2022-10-13

4.  Monoclonal gammopathies of clinical significance.

Authors:  Angela Dispenzieri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 5.  Understanding the Cryoglobulinemias.

Authors:  Alejandro Fuentes; Claudia Mardones; Paula I Burgos
Journal:  Curr Rheumatol Rep       Date:  2019-11-19       Impact factor: 4.686

Review 6.  Diagnosis and management of monoclonal gammopathy of clinical significance.

Authors:  Hyungwoo Cho
Journal:  Blood Res       Date:  2022-04-30

Review 7.  Cutaneous manifestations of acute kidney injury.

Authors:  Gavin A Esson; Amaani B Hussain; Simon J Meggitt; Nick J Reynolds; John A Sayer
Journal:  Clin Kidney J       Date:  2021-12-09

Review 8.  Human hepatitis viruses-associated cutaneous and systemic vasculitis.

Authors:  Chrong-Reen Wang; Hung-Wen Tsai
Journal:  World J Gastroenterol       Date:  2021-01-07       Impact factor: 5.742

9.  Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia.

Authors:  Wei Bai; Lixia Zhang; Jiuliang Zhao; Shangzhu Zhang; Jiaxin Zhou; Xiaomei Leng; Zhengyin Liu; Wenling Ye; Bing Han; Xinping Tian; Mengtao Li; Yan Zhao; Xiaofeng Zeng
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

10.  Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis.

Authors:  Laura Gragnani; Serena Lorini; Silvia Marri; Umberto Basile; Veronica Santarlasci; Monica Monti; Francesco Madia; Luisa Petraccia; Cristina Stasi; Niccolò Marello; Cecilia Napodano; Francesco Annunziato; Anna Linda Zignego
Journal:  Hepatology       Date:  2021-05-26       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.